Copyright
©The Author(s) 2023.
World J Gastrointest Oncol. Aug 15, 2023; 15(8): 1486-1496
Published online Aug 15, 2023. doi: 10.4251/wjgo.v15.i8.1486
Published online Aug 15, 2023. doi: 10.4251/wjgo.v15.i8.1486
Table 3 Diagnostic performance of hepatocellular carcinoma, early hepatocellular carcinoma, and different subgroups of hepatocellular carcinoma in the NSMC-hepatocellular carcinoma model
Cut-off value | Training cohort | Validation cohort | |||||||||
AUC (95%CI) | SEN (%) | SPE (%) | PPV (%) | NPV (%) | AUC (95%CI) | SEN (%) | SPE (%) | PPV (%) | NPV (%) | ||
HCC | 0.22 | 0.960 (0.950-0.971) | 94.40 | 95.35 | 87.25 | 98.10 | 0.966 (0.945-0.986) | 90.00 | 94.20 | 89.87 | 95.47 |
Early HCC | 0.946 (0.901-0.991) | 85.93 | 93.62 | 61.11 | 98.28 | 0.947 (0.901-0.994) | 89.10 | 98.49 | 94.23 | 97.02 |
- Citation: Liu ZJ, Xu Y, Wang WX, Guo B, Zhang GY, Luo GC, Wang Q. Development and application of hepatocellular carcinoma risk prediction model based on clinical characteristics and liver related indexes. World J Gastrointest Oncol 2023; 15(8): 1486-1496
- URL: https://www.wjgnet.com/1948-5204/full/v15/i8/1486.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v15.i8.1486